Locally Advanced Non-Small Cell Lung Cancer

Datopotamab deruxtecan improved PFS compared with standard chemotherapy for patients with advanced non-small cell lung cancer, according to topline data released by the agent’s manufacturer.

The FDA granted regular approval to selpercatinib for treatment of certain patients with non-small cell lung cancer.

A 2-year update on Checkmate9LA suggested that combining nivolumab with ipilimumab and two cycles of chemoradiation may be better than four cycles of chemoradiation alone, according to a speaker at the virtual 2021 ASCO Annual Meeting.